ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
| 대상 질환 | Ovarian Cancer |
|---|---|
| 임상 단계 | 1/2상 |
| 스폰서 | Michael McHale |
| 상태 | 조기 종료 |
| 참여자 수 | 8 명 |
| 중재(약물) | VS-6063, Paclitaxel, Carboplatin |
| 시작일 | 2018년 2월 6일 |
| 완료일 | 2023년 7월 30일 |
| 결과 공개일 | 2026년 7월 31일 |
요약
The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.
Dose-Limiting Toxicity
| Defactinib (VS-6063) (200 mg) + Carboplatin/Paclitaxel | 1 Participants |
|---|---|
| Defactinib (VS-6063) (400 mg) + Carboplatin/Paclitaxel | 1 Participants |
Objective Response Rate (ORR)
| Defactinib (VS-6063) + Carboplatin/Paclitaxel | 0 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulo — Beth Israel Deaconess Medical Center
- Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, — M.D. Anderson Cancer Center
- Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carbop — AstraZeneca
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Trea — National Cancer Institute (NCI)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunother — National Cancer Institute (NCI)
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or — National Cancer Institute (NCI)